Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Salivary Gland Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Poly(ADP-ribose) Polymerase Inhibitors × 90 days × Clear all
NCT06502691 2026-05-19

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

University of Washington

Phase 1/2 Recruiting
22 enrolled
Breast

Breast Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡